


D3



(11) Publication number:

0 202 159
A2

(12)

EUROPEAN PATENT APPLICATION

(21) Application number: 86400977.4

(51) Int. Cl.⁴: **A 61 M 31/00**
A 61 K 9/22

(22) Date of filing: 06.05.86

(30) Priority: 10.05.85 US 732333
29.05.85 US 738633
29.05.85 US 738634

(43) Date of publication of application:
20.11.86 Bulletin 86/47

(84) Designated Contracting States:
CH DE FR GB IT LI NL

(71) Applicant: MERCK & CO. INC.
126, East Lincoln Avenue P.O. Box 2000
Rahway New Jersey 07065(US)

(72) Inventor: Gardner, Colin R.
525 Lawrence Avenue
Lawrence Kansas 66044(US)

(72) Inventor: Caldwell, Larry J.
2709 Princeton Boulevard
Lawrence Kansas 66044(US)

(72) Inventor: Cargill, Robyn C.
937 Alabama
Lawrence Kansas 66044(US)

(72) Inventor: Higuchi, Takeru
2811 Schwarz Road
Lawrence Kansas 66044(US)

(74) Representative: Ahner, Francis et al.
CABINET REGIMBEAU 26, avenue Kléber
F-75116 Paris(FR)

(54) Drug delivery device which can be retained in the stomach for a controlled period of time.

(57) Drug delivery device retained in the stomach comprising at least one drug and a continuous solid-stick figure, a planar figure or ring figure made from polymer(s) that releases said drug slowly over a controlled, predictable and extended period of time.

EP 0 202 159 A2

BEST AVAILABLE COPY

2289S/0919A

86400977 0202159

- 1 -

IX122Y

TITLE OF THE INVENTION

DRUG DELIVERY DEVICE WHICH CAN BE RETAINED IN THE
STOMACH FOR A CONTROLLED PERIOD OF TIME

5 DESCRIPTION OF THE PRIOR ART

Numerous patents and publications have
described devices which can be retained in the
stomach for extended periods of time. The prior art
can be categorically described according to the
10 technologies listed below:

- 1.) Floating devices
- 2.) Swelling devices
- 3.) Inflating balloons and
- 4.) For ruminant animals--various shapes.

15

20

There follows a discussion of each of the above technologies which demonstrates the technological advancement of the invention over the prior art:

(1) Michaels et al (Alza Corporation), U.S. Patent No. 3,901,232, describe a device which contains a drug delivery compartment attached to an envelope which is contained within an erodible capsule. Upon ingestion, the capsule dissolves and a liquid contained in the envelope vaporizes and swells the envelope to provide a means of retention by flotation within the desired body cavity e.g. the stomach.

S. Watanabe et al, U.S. Patent No. 3,976,764 teach the use of a hollow or low density core surrounded by polymeric materials containing drug(s). The device floats in the stomach and releases said drug over an extended period of time.

Sheth and Tossounian, U.S. Patent Nos. 4,140,755 and 4,167,558 describe the use of a tablet which is hydrodynamically balanced to be buoyant under gastric conditions thereby remaining in the stomach for an extended period of time.

All of the references in this category function on the basis of floatation or buoyancy and do not teach the use of size to retain them in the stomach.

(2) Johnson et al, U.S. Patent No. 3,574,820 teach the use of tablets or capsules containing a reaction product of gelatin and N-acetyl-homocysteine thiolactone as a component of an oral dosage form small enough to be swallowed but which swells in the stomach to become too large to pass through the pylorus.

Banker, U.S. Patent No. 261,242 describes the use of a swellable polymer (e.g. Gantrez) coated on the outside of tablets or capsules such that the coating swells under gastric conditions.

5 Mamajek and Moyer, U.S. Patent No. 4,207,890 teach the use of an expandable envelope containing a drug and an agent which expands when gastric fluid permeates through the envelope. The device enlarges and is retained in the stomach for an extended
10 period. There is no teaching as to how the device disintegrates or what controls its exit from the stomach.

Theeuwes and Urquhart, U.S. Patent No. 4,434,153 describe the use of a device (containing a
15 hydrogel) which can enter into the gastrointestinal environment where it imbibes fluid and swells 2-50 fold so that it is retained in the stomach over an extended period. Small pills containing drug are released from this device and subsequently delivered
20 for gastric or intestinal absorption.

The patents of this category teach the use of size to retain the device in the stomach and function by absorption of gastric fluid to cause swelling of an expandable polymeric material. No
25 indication of the obtainable duration is given or of control of the process by which the device disintegrates or otherwise is expelled from the stomach.

(3) Alza Corporation, U.S. Patent Nos.
30 3,797,492 and 3,901,232 disclose the use of inflatable bags containing a gas or vapor-generating system to cause inflation following release of the device from a bioerodible capsule in the stomach (or other

desired body cavity). The inflated envelope causes the device to be retained in the desired site (e.g. stomach) and drug is released from an attached delivery system. When all the drug has been expelled
5 the envelope deflates and the device passes from the stomach.

These patents imply the use of size to retain the device in the stomach and achieve enlarged size in the stomach via conversion of liquid (or
10 solid) components to a gaseous form. They do not teach the use of mechanical movement to create large forms of the device from a smaller configuration.

(4) R. Laby, U.S. Patent No. 3,844,285 describes the use of a device having one initial
15 configuration or adapted to be arranged in the configuration so as to pass into the rumen of an animal, whereupon, it changes to a second configuration which will prevent or hinder regurgitation of the device. This patent is applicable to devices
20 which are delivered to the rumen and required to remain in the rumen by preventing regurgitation. The reference does not teach devices designed to enter and be retained in the stomach of humans or other non-ruminant animals. Neither does it teach any
25 procedure for preventing passage of such devices through the pylorus of humans or non-ruminant animals since only regurgitation is hindered or prevented by the device of the reference. The anatomy of the rumen is quite different from that of the stomach of
30 non-ruminant species.

BACKGROUND OF THE INVENTION

The invention provides a drug delivery ←
device comprising at least one drug and a continuous
solid-stick figure, a planar figure or ring figure
5 made from polymer(s) that is retained in the stomach
for predictable and extended periods of time for
releasing therapeutic or other beneficial agents.

Many orally administered drugs fail to
achieve their full potential because of a number of
10 problems including:

- a. Slow and incomplete intestinal absorption.
- b. Existence of preferential absorption sites
in the gastrointestinal tract (absorption
windows).
- 15 c. Short biological half-life (in particular if
the therapeutic index is low).

Solutions to the delivery problems for these
agents cannot be guaranteed using conventional
20 controlled release technology since the site of drug
release may be beyond the site of optimal absorption
or the transit time through the absorbing portion of
the gastrointestinal tract may be too short to effect
an increase in the duration of action of the drug.
25 In order to optimize the delivery of these agents to
achieve maximum effectiveness (and reduce
concentration-related side effects) it is desirable
to obtain a drug delivery device which would be
retained in the stomach for a prolonged, predictable
30 period of time during which it would release the
agent in a predetermined pattern. At the end of its
period of usefulness, the device would disintegrate
or otherwise alter its properties such that it would
exit from the stomach and pass down the intestine.

0202159

2289S/0911A

- 6 -

IX122Y

Accordingly, it is an object of the invention to provide a means of retaining the dosage form in the stomach for an extended, predictable period of time. (Thereby the duration of absorption and hence the duration of action of drugs with short biological half-lives could be extended.) Likewise the bioavailability of the agents could be improved over that achieved from a conventional dosage form or conventional sustained release preparation.

Another object of the invention is to provide a mechanism whereby after a predetermined time the device will erode, disintegrate or otherwise alter its properties and pass out of the stomach and into the intestine. In addition the device should not lodge in the intestine thereby causing an obstruction.

A further object is to devise a device which will not obstruct the passage of food while the device is in the stomach or after it has passed into the intestine.

Other objects, features and advantages of the invention will be apparent to one skilled in the art from the detailed description of the invention which follows.

Immediately after consumption of food, the stomach acts as a holding tank for the solids while they are digested and broken down into small particles (1-2 mm in diameter) by the action of acid, enzymes and the physical grinding of the food particles by muscular contractions of the stomach wall. Due to the sieving action of the pyloric valve only particles of the order of 1-2 mm leave the

stomach and pass into the intestine during the digestive period. Approximately two hours after digestion of a meal, the stomach passes into its interdigestive phase during which there are regular and frequent (every 1-1/2 - 2 hours) periods of intense contraction known as the interdigestive migratory myoelectric complex (IMMC). These contractions which can apply forces up to 200 cm of water (approximately 0.2 atmospheres pressure) are designed to remove any remaining ingested food from the stomach through a fully open pylorus. Clearly, then, any dosage form which is designed to remain in the stomach for an extended period (i.e., greater than a few hours) must be capable of withstanding these contractive forces to prevent it from passing from the stomach into the intestine.

A BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 is a preferred configuration of a continuous solid-stick figure device in a tetrahedral form with fastened ends.

Figure 1a is a preferred configuration of the device in a tetrahedral form.

Figure 1b is formed when corner 1 and 3 and corners 2 and 4 of Figure 1a are compressed together.

Figure 1c refers to encapsulation of Figure 1(b).

Figure 2 is a preferred configuration of a planar figure device in a 4-lobed planar form.

Figures 2a and 2b show the device of figure 2 folded and inserted into a capsule for oral administration.

Figure 3 is a preferred configuration of the device in a planar, disc-shaped form.

Figures 4a and 4b show the device of figure 3 folded and inserted into a capsule for oral administration.

Figure 5 is a preferred configuration of the device in a planar, 4-limbed cross form. Each limb of the device contains a rigid, soluble polymer which slowly erodes resulting in loss of integrity of the device.

Figures 6a and 6b show the device of figure 5 folded and inserted into a capsule for oral administration.

Figure 7 is a preferred configuration of a ring figure device in a ring form.

Figure 8a shows the device in a folded configuration.

Figure 8b refers to encapsulation of Figure 8a.

DESCRIPTION OF THE INVENTION

The invention is directed to a gastric retention device comprising a continuous stick figure prepared from at least one erodible polymer, said device having the following properties:

- a) compressible to a size suitable for swallowing;
- b) expandable to size which will prevent passage through the pylorus for a predetermined time;
- c) sufficiently resistant to a simultaneous force in two directions by

- a stomach to prevent passage through a pylorus for a predetermined time; and
- d) erodible in the presence of gastric juices so that said device after a predetermined time is no longer able to retain or attain the expanded configuration defined in (b) above and/or resist a simultaneous force in two directions as defined in (c) above.

10 The invention is also directed to a method for the controlled release over a period of time of a drug in the stomach, comprising a continuous stick figure prepared from at least one erodible polymer, said device having the following properties:

- 15 a) compressible to a size suitable for swallowing;
- b) expandable to size which will prevent passage through a pylorus for a predetermined time;
- 20 c) sufficiently resistable to a simultaneous force in two directions by a stomach to prevent passage through a pylorus for a predetermined time; and
- d) erodible in the presence of gastric
- 25 juices so that said device after a predetermined time is no longer able to retain or attain the expanded configuration defined in (b) above and/or resist a simultaneous force in
- 30 two directions as defined in (c) above.

Definitions:

Gastric retention device is a device which resides in the confines of the stomach for the purpose of providing a platform for controlled release of biologically active agents.

Continuous solid-stick figure refers to a framework composed of more or less rigid rods or sticks (preferably a Tensile Modulus of at least 1×10^3 to 50×10^6 psi, more preferably in the range of 1.5×10^4 to 20×10^6 psi) which are bent and/or fastened together in a manner such that the framework will not pass out of the stomach, but will allow passage of food. Preferred configurations are illustrated in Figures 1, 1a, 1(b) and 1(c).

The expanded tetrahedral device shown in Figures 1 is compressed by squeezing together corners 1 and 3 and corners 2 and 4 of Figure 1(a) by applying forces at right angles to subsequently obtain the form of Figure 1(b) and ultimately inserted into a hard gelatin capsule as illustrated in Figure 1(c).

A planar disc-shaped or multi-lobed flat or planar device may be used which is large enough and rigid enough such that said device will not pass out of the stomach but will allow passage of food around said device. Preferred configurations are illustrated in Figures 2-6.

The longest diameter (the device need not be symmetrical) of the device may vary between 1.6 and 5 cm; more preferably in the range 2.0 to 4 cm; and most preferably in the range 3.2 to 3.6 cm.

The expanded devices shown in Figures 2, 3 and 5 are compressed by folding or rolling to

subsequently obtain the form of Figures 2a, 4a, and 6a respectively and ultimately inserted into capsules as illustrated in Figures 2b, 4b and 6b.

5 A ring refers to an annulus as shown in Figure 7. The ring is preferably made of a non-erodible extruded rod-shaped material and then merely joining the ends with an erodible material. However, the whole ring may be made of erodible material.

10 The diameter of the ring may vary between 1.6 and 5 cm; more preferably in the range 2.5 to 4 cm; and most preferably in the range 3.2 to 3.6 cm.

The cross-section of the band making up the circumference of the annulus may be one of many shapes (e.g., circular, rectangular, square, 15 triangular and the like). The dimensions of the cross-section should be in the range 0.5 to 5 mm, more preferably in the range 1 to 3 mm. The cross-section may be solid or hollow; i.e., the ring 20 may be constructed from a tube which may be empty or may contain liquid, solid or gaseous material.

The ring shown in Figure 7 may be folded as shown in Figure 8a and inserted into a capsule (Figure 8b) for oral administration.

25 Criterion A means that the desired expanded configuration of said device is too large to be swallowed and thus must be compressed and contained in a conventional capsule or like container for swallowing. The capsule is designed to dissolve 30 after oral ingestion within the confines of the stomach.

Criterion B means that after the compressed device within the capsule container reaches the stomach, upon dissolution and/or disintegration of the retaining capsule or like container, said device

will expand or unfold in such a manner that results in its original shape which is too large to pass from the stomach into the intestine unless enough force is applied to recompress the device. This "expanded" form of the device will remain in the stomach for a pre-determined period of time depending on the desired time profile of release of the biologically active agent, which is a part of the device or contained within a controlled release module that is attached to the retention device. The "pre-determined time" is preferably within the range of 1 hour to 1 year. For example, a biologically active agent which prevents heart-worm infestation in dogs might require gastric retention and controlled delivery of said agent over the course of 6-12 months. This period depends on the seasonal changes of the mosquito population which is the main vector of heart worm infection in dogs. A second example is the use of such a gastric retention device to maintain controlled delivery of a contraceptive agent. The desired retention time of the device might be 3-4 weeks to coincide with the normal frequency of menses. A third example is the use of such a device to achieve once daily dosing, if such device is coupled to a controlled release device for delivery of an agent with a very short half-life of biological activity, such as a dopamine agonist for treatment of Parkinsonism.

Criterion C means that the device in question must sustain some compressive force, in excess of that amount the stomach is able to apply, in order for said device to not prematurely pass on into the

intestine. For humans and animals with similar gastric anatomy such as dogs, the gastric pouch is capable of applying forces of 50-150 grams.

Criterion D means that after some pre-determined time, during which said device has been utilized, some part of the device will suddenly or gradually fail to meet Criteria B and/or C. That is, the device will either be unable to withstand a lesser compressive force, or will lose its integrity as a single unit, and thereby be subject to the normal propulsive forces and pass out of the stomach. By doing so, the danger of multiple devices causing obstructive problems, is obviated.

These devices can be manufactured by a number of processes including injection molding, extrusion, film-forming, laminating and the like as will be clear to one skilled in the art. For example, a mold can be constructed in the desired shape of the device and filled with appropriate material(s) in the liquid state and then allowed to cure by chemical processes or cooling if thermosetting materials(s) is used.

A critical property of the devices is that, after a certain, pre-determined period of time in the stomach they will alter their properties in a manner which will permit their elimination from the stomach into the intestine. For this purpose the devices must contain components(s), sections(s) or points(s) which will erode or dissolve in the aqueous environment of the stomach.

For example, the four lobes of the device of figure 2 may be fastened at a central point by glue (or other material) which will dissolve or erode

during the desired time period, thereby liberating the individual lobes which will then easily pass out of the stomach.

5 The disc can be manufactured from composite materials such that one or more components(s) will erode or dissolve leaving a disc whose mechanical properties are such that it can be readily removed from the stomach by the compression forces associated with the recurrent interdigestive migratory
10 myoelectric complex.

 A further modification of the four-lobed form is to have contained within the lobes an erodible or dissolving structure which will maintain the lobes in a rigid configuration until the
15 internal, structurally supporting material has disintegrated. At that point the device would be incapable of maintaining its rigid, planar conformation and would be eliminated from the stomach. (see figure 3 and Example 11).

20 Although the polymers may be blends, combinations, composites or copolymers (erodible and non-erodible), said polymers must be erodible at the point(s) of desired dissolution and/or disintegration. Representative erodible polymers which can be employed
25 in the practice of the invention are cellulose such as Klucel (hydroxypropylcellulose), cellulose acetate phthalate, methyl cellulose, hydroxypropylmethyl-cellulose phthalate and the like; ethylene/vinyl alcohol copolymer; ethylenemaleic anhydride
30 copolymer; polyacrylates such as Eudragit E (cationic copolymer based on dimethylaminoethyl methylacrylate and neutral methylacrylic acid esters), poly(acrylic acid), poly(methacrylic acid) and the like; polylactones such as poly(caprolactone) and the like;

polyanhydrides such as poly[bis-(p-carboxyphenoxy)-
propane anhydride], poly(terephthalic acid anhydride)
and the like; polyvinyl pyrrolidone; polyamides and
polypeptides such as polylysine, polyglutamic acid
5 and the like; gelatin and derivatives such as those
produced on reaction with N-acetyl-homo-cysteine
thiolactone and the like; polyesters such as
polylactides, polyglycolides, poly(betahydroxybutyric
acid) and the like; poly(ortho esters) such as
10 copolymers of DETOSU with diols such as hexane diol,
decane diol, cyclohexane dimethanol, ethylene glycol,
polyethylene glycol and incorporated herein by
reference those poly(ortho) esters described and
disclosed in U.S. Patent No. 4,304,767 and the like;
15 polyurethanes such as those prepared with
poly(tetramethylene oxide), prepolymer terminated
with hexamethylene diisocyanate and a poly functional
diester of oxalic acid and glycerol,
di-(2,3-dihydroxypropyl)oxalate or its mixture with
20 3,6-dioxaoctane-1,8-diol and the like;
polyacrylonitriles such as poly(alkyl- α -cyano-
acrylates) wherein the alkyl is methyl, ethyl,
propyl, butyl, amyl and the like; and types of
inorganic glass based on polyphosphates and fused
25 salts.

Representative non-erodible polymers that
may be employed in the practice of the invention are
polyolefins such as polyethylene, polypropylene,
ethylene vinyl acetate copolymers, poly(tetrafluoro-
30 ethylene) and the like; rubbers such as silicon based
rubber, styrene-butadiene copolymers and the like
polyamides such as nylon 6,6, nylon 6, and the like;
polyesters such as poly(ethylene terephthalate) and

the like; polyurethanes formed from diisocyanates such as 1,6-hexane diisocyanate or biphenylene diisocyanate etc. and diols such as ethylene glycol, 1,4-butane diol and the like; and cellulose such as ethyl cellulose, cellulose diacetate, cellulose triacetate and the like.

A drug or medicament may be associated with the gastric retention device in different ways, depending on the physical and chemical properties of the drug or medicament. For example, the drug may be dispersed as a solution or suspension within an erodible polymer matrix such that as the matrix erodes within the confines of the gastric pouch, the drug is released at a predetermined rate. Similarly, the drug may be dissolved or dispersed within a non-erodible matrix material comprising part of the retention device. As this matrix comes in contact with gastric fluid, the drug diffuses out of the non-erodible matrix at a predetermined rate. An alternative to incorporating the drug as an integral part of the gastric retention device is to simply fasten a controlled release drug module to the retention device. Such a module might be a miniature constant-flow pump, either mechanically or osmotically driven, and may be fastened to the retention device by gluing or tethering. Likewise it may consist of a matrix system, erodible or non-erodible, fastened to the retention device.

In man and similarly-sized non-ruminant mammals, the size of the pyloric valve between the stomach and small intestine is generally in the range of 3-5 cm maximum inner circumference. Objects with a minimum circumference of more than 5 cm will

generally not pass from the stomach through the pylorus. The stick-figure, planar figure and ring figure devices described herein are designed to present a minimum circumference of more than 5 cm after deployment in the stomach. Before deployment in the stomach the minimum circumference is less than 2 cm.

To further set forth the concept of the invention several gastric retention studies are shown below.

Studies were performed with Beagle dogs in order to ascertain gastric retention time of the drug delivery device described herein. The parameters investigated were size, erodibility and polymer flexibility. These devices were administered in gelatin capsules and their position in the gastrointestinal tract determined using x-ray techniques. Each device was tested in three to four different dogs in three fed states: fed (fed 10 minutes before dosing and food ad lib thereafter) fed/fast (fed 10 minutes before dosing, and fasted thereafter for 36 hours), and fast (fasted 18 hours before dosing and thereafter for 36 hours).

The results for a tetrahedral device of different dimensions are shown below.

0202159

2289S/0919A

- 18 -

IX122Y

Shape	Dimensions	Average	
		% Retained	N*
		24 hours	
5	Tetrahedron 2.0 cm (wide) x 2.0 cm		
	(long) x 2.0 cm (high)	92	12
	1.5 cm x 1.5 cm x 1.5 cm	85	12

*Number of trials.

10

Polymer flexibility studies were also carried out in Beagle dogs. One point five millimeter (1.5 mm) diameter rods having varying flexibilities were extruded. These rods were constructed of polyethylene alone, polyethylene blended in various proportions with a copolymer of ethylene (86%) and vinyl acetate (16%) or the copolymer of ethylene and vinyl acetate alone. All rods also contained 15% by weight of barium sulfate to render them visible by x-ray in the g.i. tract of the dogs.

Shape	Material	Tensile	%	
		Modulus	Retained	N
		(psi)	at 24 hours	
25	100% PE	11,556	92	12
	Tetrahedron PE 94%/EVA 6%	11,383	57	7
	(2 cm) PE 30%/EVA 70%	9,512	50	4
30	100% EVA	3,828	50	4

EVA composition 86% ethylene, 14% vinylacetate
PE is polyethylene

2289S/0919A

- 19 -

IX122Y

Studies were conducted on the degree of erodibility of the polymeric materials described within the invention. A series of poly(ortho ester)/polyethylene (POE/PE) blends have been tested in Beagle dogs using a modified tetrahedron device. The tetrahedron shape was formed from four silastic, 15% barium-load corners with openings for insertion of the poly(ortho ester)s/polyethylene rods. The corner pieces were 3 mm thick and formed an equilateral triangle. The completed tetrahedron measured 2x2x2 cm (see figure I). All dogs were tested in the fasted state (fasted 18 hours before dosing and thereafter for 36 hours) and the following data obtained.

15

	<u>**POE/PE</u>	<u>% Retained at 24 hours</u>	<u>N</u>
	50/50	80	5
	65/35	80	5
20	75/25	100	5
	80/20	0	4
	85/15	25	4
	90/10	0	5

25 **POE used was prepared from cis-trans cyclohexane-dimethanol and 3,9-Bis(ethylidenyl)-2,4,8,10-tetraoxaspiro[5,5]undecane [Detosu]

30 In vitro dissolution studies were carried out with the poly(ortho ester)/polyethylene blends. One inch pieces of the 1.5 mm diameter rod blends were tested in pH 1.5 buffer, in a 37°C water/shaker bath. At selected time intervals a piece was removed

0202159

2289S/0919A

- 20 -

IX122Y

from the water/shaker bath and measured gravimetrically. Percent erosion was calculated from weight loss as shown below.

5 In Vitro Dissolution - % Poly(ortho ester) Eroded

		Poly(ortho ester)/Polyethylene				
Time						
(hours)		50/50	65/35	75/25	80/20	85/15
10	8	35.4	40.9	53.2	95.1	99.3
	16	55.2	77.2	86.9	97.9	97.3
	24	72.0	84.0	84.4	98.8	96.6
	28	74.6	90.5	86.4	98.1	96.8
15	32	87.4	88.2	87.5	98.3	98.4

The experimental error is about $\pm 10\%$.

Studies were performed with Beagle dogs in order to ascertain gastric retention time of the drug delivery device described herein. The parameters investigated were size, erodibility and polymer flexibility. These devices were administered in gelatin capsules and their position in the gastrointestinal tract determined using x-ray techniques. Devices were tested in three to four differing dogs which were fasted 18 hours before dosing and thereafter for 36 hours. The effect of size (ring diameter) on gastric retention time is shown in Table I below.

30

TABLE I

	Shape	Dimenions	Average % Retention at 24 Hours	N*
5	Ring	3.6 cm diameter	100	6
	Ring	2.5 cm diameter	70	10

*N=Number of trials

Polymer flexibility studies were also carried out in Beagle dogs. One point five millimeter (1.5 mm) diameter rods having varying flexibilities were extruded. These rods were constructed of polyethylene alone, polyethylene blended in various proportions with a copolymer of ethylene (86%) and vinyl acetate (16%) or the copolymer of ethylene and vinyl acetate alone. These rods were formed into rings and inserted into capsules for in vivo testing. Rings were also constructed from SilasticTM (Dow Company) medical grade silicone rubber. All rings also contained 15% by weight of barium sulfate to render them visible by x-ray in the g.i. tract of the dogs. See Table II below.

TABLE II

	Shape	Material	Tensile Modulus (psi)	% Retained at 24 hours	N
25		100% PE	11,556	100	6
	Rigid Ring	PE 94%/EVA 6%	11,383	100	4
	(3.6 cm)	PE 30%/EVA 70%	9,512	75	4
30		100% EVA	3,828	0	4
	Soft Ring	silicone rubber	ND*	67	9
	(3.0 cm)				

0202159

2289B/0919A

- 22 -

IX122Y

EVA composition 86% ethylene, 14% vinylacetate
PE is polyethylene

*N.D.=not determined. This ring was very flexible.

To demonstrate that a ring could rapidly
5 exit from the stomach when its integrity was lost,
unsealed rings (i.e. strings) were administered to
dogs in gelatin capsules and then gastric retention
measured by X-ray techniques. The data are shown in
Table III below:

10

<u>III</u>				
				Gastric
				Retention
				Time
15	Shape	Material	Size	(hours) N
	String	Silastic	6 cm long 1.5 mm diameter	40-70 2

These results demonstrate that if a ring
20 contains an erodible section which can be ruptured at
a predetermined time, the resultant string will be
eliminated from the stomach.

The erodible section(s) can be constructed
from many different types of material. Examples of
25 erosion profiles of some such materials (blends of
polyethylene and a poly(orthoester) are shown in the
Table IV below.

30

0202159

2289S/0919A

- 23 -

IX122Y

In Vitro Dissolution - % Poly(ortho ester) Eroded

<u>Poly(ortho ester*)/Polyethylene</u>						
Time						
	(hours)	50/50	65/35	75/25	80/20	85/15
5						(% by weight)
	8	35.4	40.9	53.2	95.1	99.3
	16	55.2	77.2	86.9	97.9	97.3
10	24	72.0	84.0	84.4	98.8	96.6
	28	74.6	90.5	86.4	98.1	96.8
	32	87.4	88.2	87.5	98.3	98.4

The experimental error is about $\pm 10\%$.

15

*The poly(orthoester) used was a copolymer of cis-trans cyclohexane dimethanol and 3,9-Bis-(ethylidenyl)-2,4,8,10-tetraoxaspiro[5,5]undecane (Detosin).

20

The active agents (therapeutic agent or other beneficial agents) which can be utilized in accordance with the practice of the invention is not critical. Any agent which can be obtained in a stable form is applicable herein. As to the amount of active agent which can be delivered in accordance with the invention, said amount depends on a variety of factors such as the host, physical attributes, particular disease or disorder being treated and of course the severity of the condition being treated.

25

30

The amount of active agent utilizable in the invention is known to one skilled in the art and is

disclosed in various medical references such as PDR and etc. or could be obtained from suitably designed clinical trials.

5 Generally, the amount of polymer employed in the practice of the invention ranges from 10% to 99.9% polymer (preferably 20% to 60%) by weight of the drug delivery platform. The remaining portion of the composition contains the medicament and conventional pharmaceutically acceptable excipients.

10 Representative pharmaceutically acceptable excipients that the drug delivery device may contain are buffering agents and preservatives. Suitable water soluble preservatives which may be employed in the drug delivery device are sodium bisulfite, sodium
15 thiosulfate, ascorbate, benzalkonium chloride, chlorobutanol, thimerosal, phenylmercuric borate, parabens, benzyl alcohol and phenylethanol. These agents may be present in amounts from 0 to 5% by weight. Suitable water soluble buffering agents are
20 alkali or alkali earth carbonates, phosphates, bicarbonates, citrates, borates, acetates, acid anhydrides, succinates and the like, such as sodium phosphate, citrate, borate, acetate, bicarbonate and carbonate. These agents may be present in amounts
25 sufficient to maintain some optimum pH of the system in the range 1 to 9. As such the buffering agent can be as much as 25% on a weight to weight basis of the total composition.

30 The following examples illustrate the preparation of various drug delivery devices of the invention. The Examples should be construed as illustrations rather than limitations thereof.

EXAMPLE 1

A modified tetrahedron was constructed from four Silastic (polydimethylsiloxane) 15% barium-loaded corners with openings for insertion of the poly(ortho ester) (65/35 HD/tCDM)/polyethylene blend rod (Fig. 1). The completed tetrahedron measured 2x2x2 cm and fit into a 000 gelatin capsule. A biologically active compound may be incorporated into the erodible rod or the silastic corners.

The poly(ortho ester) (a copolymer of 65% hexane diol, 35% trans-cyclohexane dimethanol with DETOSU 65/35 HD/tCDM)/polyethylene blends were tested in Beagle dogs using x-ray techniques. All dogs were dosed in the fasted state (fasted 18 hours before dosing and thereafter for 36 hours). (See Table IV).

Table IV

20	Material	Percent Retained	
		at 24 hrs in Stomach	N*
	Poly(ortho ester) (65/35 HD/tCDM)/poly- ethylene		
	50/50 Blend	100	4
25	60/40 Blend	67	3

*Number of trials.

30

EXAMPLE 2

Following the procedure of Example 1, the rods that formed the tetrahedral configuration of the stick figure were fabricated from Klucel HF

2289S/0919A

- 26 -

IX122Y

(hydroxypropylcellulose)/polyethylene blends. In vivo performance in dogs is shown in Table V.

Table V

5

Material	Percent Retained	
	at 24 hrs in Stomach	N
Klucel HF/polyethylene		
75/25 Blend	100	4
90/10 Blend	50	2

10

EXAMPLE 3

Following the procedure of Example 1, the rods that formed the tetrahedral configuration of the stick figure were fabricated from poly(ortho ester) (c,tCDM)/polyethylene blends. Results are given in the following tables. In vivo performance in dogs is shown in Table VI.

20

Table VI

Poly(ortho ester) (c,tCDM***)/Polyethylene	Percent Retained at	
	24 hrs in Stomach	N
50/50	80	5
65/35	80	5
75/25	100	5
80/20	0	4
85/15	25	4
90/10	0	5

30

*** c,tCDM represents a copolymer of cis,trans cyclohexanedimethanol with Detosu.

EXAMPLE 4

Following the procedure of Example 1, the rods that formed the tetrahedral configuration of the stick figure may be fabricated from blends of poly(ortho ester) (65/35 HD/tCDM)/polypropylene..

EXAMPLE 5

Following the procedure of Example 1, the rods that formed the tetrahedral configuration of the stick figure may be fabricated from blends of Hydroxypropylmethylcellulose phthalate (HPMCP)/polyethylene.

EXAMPLE 6

Following the procedure of Example 1, the rods that formed the tetrahedral configuration of the stick figure may be fabricated from Eudragit E with methylcellulose.

EXAMPLE 7

This example demonstrates the utility of a tetrahedral configuration that may be made solely from blends of poly(ortho ester) (65/35 HD/tCDM)/polyethylene. The completed tetrahedron measures 2x2x2 cm and fits into a number "0" gelatin capsule for dosing (Fig. 1a, b and c). A biologically active compound may be incorporated into the erodible material or otherwise contained in an attached drug reservoir via conventional formulation procedures.

EXAMPLE 8

Following the procedure of Example 7, the material that formed the tetrahedral shape may be fabricated from a poly(ortho ester) (65/35 HD/tCDM)/EVA blend.

EXAMPLE 9

Following the procedure of Example 7, the material that formed the tetrahedral shape may be fabricated from a Klucel HF/polypropylene blend.

5

EXAMPLE 10

Studies were performed with Beagle dogs in order to ascertain gastric retention time of the drug delivery device described herein. The parameters investigated were size, shape and erodibility. These devices were administered in gelatin capsules and their position in the gastrointestinal tract determined using x-ray techniques.

The results for disc and 4-lobed planar devices of different dimensions and made from Silastic (Dow Company) medical grade silicone rubber labelled with 15% barium sulfate are shown below.

20	Shape	Dimensions	% Retained	N*
			at 24 hrs.	
	Disc	2.5 cm diameter	67	9
	4-lobed figure	3.2 cm diameter	90	10
		2.7 cm diameter	83	12
25		2.2 cm diameter	60	10

* Number of trials

These data indicate that the retention of these devices in the stomach is a function of their diameter and that retention for a period of 24 hours is possible using devices which can be folded into gelatin capsules suitable for swallowing.

30

EXAMPLE 11

The effect of erosion on the performance of one of the devices is demonstrated in this example. The planar cross form shown in figure 5 was constructed containing segments of rigid, bioacceptable material. For this example segments of spaghetti were inserted into hollows in the limbs of the cross. When the device came into contact with water, the spaghetti segments absorbed water and lost their rigidity. The overall effect was to produce a device which had lost its integrity and which could be more readily expelled from the stomach by the forces of the interdigestive migratory myoelectric complex. The data from one such experiment using Beagle dogs are shown below.

	Shape	% Retained in	
		stomach at 24 hrs.	N
20	cross with non-eroding limbs	100%	2
	cross with eroding limbs (spaghetti)	71%	7
25	cross with empty limbs	57%	7

The data show that the cross-form with hollow limbs is much less well retained than the same shape with rigid, non-eroding limbs. The device with initially rigid, but eroding, limbs was intermediate in performance.

2289S/0919A

- 30 -

IX122Y

EXAMPLE 12

The ring may be fabricated entirely from one material which is erodible or water soluble so that
5 it slowly disintegrates in the confines of the stomach and either breaks up into smaller pieces which are expelled or is no longer able to withstand the contracting forces of the stomach wall and thereby violates criterion (c).

10

EXAMPLE 13

The ring can be formed from a blend or composite of two or more materials at least one of which is water soluble or erodible which results in
15 predetermined expulsion of the device from the stomach as in Example 12 above.

EXAMPLE 14

Example 12 or 13 where the erodible material
20 is a polyorthoester.

EXAMPLE 15

Example 12 or 13 where the water soluble material is hydroxypropylcellulose.

25

EXAMPLE 16

The ring can be constructed from a linear portion of erodible or non-erodible material whose ends are joined to form a ring using an erodible or
30 water soluble material. When this joint disintegrates the device will resort to the form of a linear rod or string which can then be expelled from the stomach.

0202159

2289S/0919A

- 31 -

IX122Y

EXAMPLE 17

Example 16 where the erodible joint is made of a poly(orthoester).

5

EXAMPLE 7

Example 16 where the water soluble joint is made of hydroxypropylcellulose.

10

EXAMPLE 8

Example 12 where the drug is contained in the erodible matrix of the ring.

15

EXAMPLE 9

Example 12 where the drug is contained in a module which is attached to the ring.

20

25

30

WHAT IS CLAIMED IS:

1. A gastric retention device comprising a continuous solid-stick figure, a planar figure or
5 ring figure prepared from at least one erodible polymer, said device having the following properties:
- a) compressible to a size suitable for swallowing;
 - 10 b) expandable to size which will prevent passage through a pylorus for a predetermined time;
 - c) sufficiently resistant to a simultaneous force in two directions by a stomach to prevent passage through a
15 pylorus for a predetermined time; and
 - d) erodible in the presence of gastric juices so that said device after a predetermined time is no longer able to
20 retain or attain the expanded configuration defined in (b) above and/or resist a simultaneous force in two directions as defined in (c) above.
2. The device of Claim 1 wherein said
25 erodible polymer is selected from the group consisting of soluble cellulosic materials, ethylene vinylalcohol, ethylenemaleic anhydride copolymer, polyacrylates, polycaprolactones, inorganic glass based on polyphosphates and fused salts,
30 polyanhydrides, poly(ortho)esters, biodegradable polyurethanes, polyvinyl pyrrolidone, polylactones, polyamides and polypeptides, gelatin and derivatives, polyacrylonitriles, polyesters and combinations thereof.

3. The device of Claim 1, wherein said device is prepared from at least one erodible polymer and at least one non-erodible polymers selected from the group consisting of polyolefins,
5 ethylenevinylacetate copolymers, rubbers, ethylene-vinylalcohol copolymers, polyamides, polyurethanes, polyesters, teflon, non-water-soluble cellulosic and combinations thereof.

10 4. The device of Claim 1 in stick figure form, wherein said figure is from 1 to 3 cm along each leg of said figure; wherein said erodible polymer is selected from the group consisting of polyolefins, ethylenevinylacetate copolymer,
15 ethylenevinylalcohol copolymer, poly(ortho)esters, cellulosics, polyanhydrides, polyamides and polypeptides, polyphosphates and fused salt and combinations, composites, blends and copolymers thereof; wherein the arms of said device have a
20 Tensile Modulus of at least 1×10^3 to 50×10^6 psi; and wherein said predetermined time is from one (1) hour to one (1) year.

25 5. The device of Claim 4, wherein said polyolefin is polyethylene or polypropylene; and said cellulosic is hydroxypropylcellulose, cellulose acetate phthalate or ethyl cellulose.

30 6. The device of Claim 4, wherein said stick figure is from 1.5 to 2.5 cm along each leg of said figure; said polymer is selected from the group consisting of a mixture of poly(ortho) ester/

2289S/0919A

- 34 -

IX122Y

polyethylene, a mixture of ethylene/vinylacetate, poly(ortho) ester and polyethylene; and said predetermined time is from 16 to 48 hours.

5 7. The device of Claim 6, wherein said polymer is a mixture of poly(ortho ester) and polyethylene.

10 8. The device of Claim 7, wherein said mixture is 75/25 poly(ortho ester)/polyethylene.

9. The device of Claim 1 wherein said polymer is a poly(ortho) ester.

15 10. The device of Claim 1 in ring figure form, wherein said ring figure is from 1.6 to 5 cm in diameter, wherein said erodible material is selected from the group consisting of polyolefins, ethylenevinylacetate copolymer, ethylenevinylalcohol
20 copolymer, poly(ortho)esters, cellulosics, polyanhydrides, polyamides and polypeptides, polyphosphates and fused salt and combinations, blends, composites and copolymers thereof; and wherein said predetermined time is from one (1) hour
25 to one (1) year.

11. The device of Claim 10, wherein said polyolefin is polyethylene or polypropylene; and said cellulosic is hydroxypropylcellulose, cellulose
30 acetate phthalate or ethyl cellulose.

12. The device of Claim 10, wherein said ring figure is from 3.2 to 3.6 cm in diameter, said material is selected from the group consisting of a

2289S/0919A

- 35 -

IX122Y

mixture of poly(ortho) ester/polyethylene, a mixture of ethylene/vinylacetate, poly(ortho) ester and polyethylene; and said predetermined time is from 16 to 48 hours.

5

13. The device of Claim 12, wherein said material is a mixture of poly(ortho ester) and polyethylene.

10

14. The device of Claim 13, wherein said mixture is a 75/25 weight ratio of poly(ortho ester)/polyethylene.

15

15. The device of Claim 1 in planar figure form, wherein said planar figure is from 1.6 to 5 cm in diameter; wherein said erodible polymer is selected from the group consisting of polyolefins, ethylenevinylacetate copolymer, ethylenevinylalcohol copolymer, poly(ortho)esters, cellulosics, polyanhydrides, polyamides and polypeptides, polyphosphates and fused salt and combinations, blends and copolymers thereof; and wherein said predetermined time is from one (1) hour to one (1) year.

25

16. The device of Claim 15, wherein said polyolefin is polyethylene or polypropylene; and said cellulosic is hydroxypropylcellulose, cellulose acetate phthalate or ethyl cellulose.

30

17. The device of Claim 16, wherein said planar figure is from 2 to 4 cm in diameter said polymer is selected from the group consisting of a

0202159

2289S/0919A

- 36 -

IX122Y

mixture of poly(ortho) ester/polyethylene, a mixture of ethylene/vinylacetate, poly(ortho) ester and polyethylene; and said predetermined time is from 16 to 48 hours.

5

18. The device of Claim 17, wherein said polymer is a mixture of poly(ortho ester) and polyethylene.

10

19. The device of Claim 18, wherein said mixture is 75/25 poly(ortho ester)/polyethylene.

0202159

1/6




Fig. 1

0202159




Fig. 1(a)




Fig. 1(b)




Fig. 1(c)

3/6





Fig. 2

0202159

4/6




Fig. 3




Fig. 4

0202159

5/6





Fig. 6

0202159

6/6






Fig. 7



a.



b.

Fig. 8

⑫

EUROPEAN PATENT APPLICATION

⑲ Application number: 86400977.4

⑥① Int. Cl.: **A 61 M 31/00, A 61 K 9/22**

⑳ Date of filing: 06.05.86

③① Priority: 10.05.85 US 732333
29.05.85 US 738633
29.05.85 US 738634

④③ Date of publication of application: 20.11.86
Bulletin 86/47

⑥④ Designated Contracting States: CH DE FR GB IT LI NL

⑥⑧ Date of deferred publication of search
report: 06.07.88 Bulletin 88/27

⑦① Applicant: MERCK & CO. INC., 126, East Lincoln Avenue
P.O. Box 2000, Rahway New Jersey 07065-0900 (US)

⑦② Inventor: Gardner, Colin R., 525 Lawrence Avenue,
Lawrence Kansas 66044 (US)
Inventor: Caldwell, Larry J., 2709 Princeton Boulevard,
Lawrence Kansas 66044 (US)
Inventor: Cargill, Robyn C., 937 Alabama, Lawrence
Kansas 66044 (US)
Inventor: Higuchi, Takeru, 2811 Schwarz Road,
Lawrence Kansas 66044 (US)

⑦④ Representative: Ahner, Francis et al, CABINET
REGIMBEAU 26, avenue Kléber, F-75116 Paris (FR)

⑤④ Drug delivery device which can be retained in the stomach for a controlled period of time.

⑤⑦ Drug delivery device retained in the stomach comprising at least one drug and a continuous solid-stick figure, a planar figure or ring figure made from polymer(s) that releases said drug slowly over a controlled, predictable and extended period of time.

EP 0 202 159 A3



European Patent
Office

EUROPEAN SEARCH REPORT

0202159

Application Number

EP 86 40 0977

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int. Cl.4)
A	EP-A-0 010 987 (BEECHAM GROUP LTD) ---		A 61 M 31/00
A	FR-A-2 526 306 (AHI OPERATIONS LTD) ---		A 61 K 9/22
A	US-A-3 944 064 (BASHAW et al.) ---		
D,A	US-A-3 844 285 (LABY) ---		
P,A	WO-A-8 600 538 (NATIONAL RESEARCH DEVELOPMENT CORP.) * Page 7, line 15 - page 8, line 13; page 9, line 33 - page 12, line 23 * -----		
			TECHNICAL FIELDS SEARCHED (Int. Cl.4)
			A 61 M A 61 K
The present search report has been drawn up for all claims			
Place of search THE HAGUE		Date of completion of the search 18-03-1988	Examiner BENZ K.F.
CATEGORY OF CITED DOCUMENTS			
X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document		T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document	

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☒ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.